argenx (EURONEXT:ARGX) posted strong Q2 2026 results—$1.5B sales up 60% YoY, operating profit +146%—driven by VYVGART growth as R&D/SG&A rise; multiple registrational readouts due H2 2026–H2 2027 while analysts lift price targets and maintain buy ratings.
Previous Week Recap
- Q2 2026 Sales Growth Driven: ARGX Q2 2026 sales $1.5B (+60% YoY, +17% QoQ) led by VYVGART uptake in gMG and CIDP; operating profit +146%; rising SG&A/R&D; key registrational readouts due H2 2026
- Empasiprubart Programs Updates: argenx (ARGX) updates empasiprubart program: EMPASSION MMN topline due Q4 2026; EMVIGORATE and EMNERGIZE CIDP toplines H2 2027; Phase 2 DGF signal and ADAPT‑Forward combo study ongoing.
- Analysts Raise Price Targets: Analysts raised price targets for argenx SE Sponsored ADR (ARGX): Guggenheim $1,185, Citigroup $1,182, Oppenheimer $1,037, RBC $1,025 — all keeping buy/outperform ratings.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.